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Abstract 
Health economic evaluation is a framework for the comparative analysis of the incremental health gains 
and costs associated with competing decision alternatives. The process of developing health economic 
models is usually complex, financially expensive and time consuming. For these reasons, model 
development is sometimes based on previous model-based analyses: this endeavour is usually referred 
to as model replication. Such model replication activity may involve the comprehensive reproduction 
of an existing model RU³borrowing´ all or part of a previously developed model structure. Generally 
speaking, the replication of an existing model may require substantially less effort than developing a 
new de novo model by bypassing, or undertaking in only a perfunctory manner, certain aspects of model 
development such as the development of a complete conceptual model and/or comprehensive literature 
searching for model parameters. A further motivation for model replication may be to  draw on the 
credibility or prestige of previous analyses which have been published and/or used to inform decision-
making. The acceptability and appropriateness of replicating models depends on the decision-making 
context: there exists a trade-off between tKH³VDYLQJV´afforded by model replication and the potential 
³FRVWV´ associated with reduced model credibility due to the omission of certain stages of model 
development. This paper provides an overview of the different levels of, and motivations for, replicating 
health economic models, and discusses the advantages, disadvantages and caveats associated with this 
type of modelling activity. Irrespective of whether replicated models should be considered appropriate 
or not, complete replicability is generally accepted as a desirable property of health economic models, 
as reflected in critical appraisal checklists and good practice guidelines. To this end, the feasibility of 
comprehensive model replication is explored empirically across a small number of recent case studies. 
Recommendations are put forward for improving reporting standards to enhance comprehensive model 
replicability. 
 
Key points for decision makers 
x Model replicability is generally perceived to be an indicator of the quality of published models.  
x Model replication is associated with both advantages and disadvantages. Replication may be 
quicker and less expensive than developing a de novo model, however model authors should 
EHDZDUHWKDWWKHVH³VDYLQJV´PD\LPSDFWXSRQWKHFUHGLELOLW\RIWKHPRGHO. 
x Our pilot study indicates that even amongst a very small sample of studies, the majority of the 
models considered could not be fully replicated.  
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INTRODUCTION 
Health economic evaluation represents a framework for the comparative analysis of the incremental 
health gains and costs associated with competing decision alternatives. Given that a single source of 
evidence, such as a randomised controlled trial (RCT), rarely provides all of the relevant information 
necessary to estimate costs and health outcomes for all decision alternatives, mathematical models are 
typically required [1]. However, the process of health economic model development is commonly 
complex, financially expensive and time consuming. For these reasons, the development of a model 
may draw on previous model-based analyses. The extent to which this is done varies between analyses: 
sometimes the new model is based only on an existing model structure, whilst in other instances the 
new model may be developed with the intention of fully reproducing the functionality and results of a 
previous model. This broad endeavour is usually termed model replication. 
The replication of models is generally undertaken using a publication and/or other written 
documentation describing the existing model. Consistent with the basic principles of the scientific 
method [2], complete replicability, at least in principle, is generally perceived to be a desirable property 
of a model and may be considered as one facet of the quality of a model-based analysis. This view is 
well supported within the literature. For example, the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) Task Force on Good Research Practices states that ³WKHGHVFULSWLRQRIWKH
PRGHOVKRXOGEHVXIILFLHQWO\GHWDLOHGWKDWWKHPRGHOFDQEHUHSOLFDWHGPDWKHPDWLFDOO\´ [3]. Similarly, 
the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist, which has 
been adopted by many journals to improve the quality of reporting of economic evaluation studies, 
recommends the reporting of all assumptions and model parameters that would be needed by a reader 
to potentially reprogram the model and to replicate its findings [4]. This general sentiment is also 
mirrored within other critical appraisal checklists and related literature on the quality assessment of 
health economic models [5-7].  
 
However, these requirements for complete replicability of models are not typically fully enforced. 
Given that the focus of such recommendations lies in the potential rather than the actual replication of 
models, authors and publishers must inevitably apply discretion in reaching judgements about whether 
model-based health economic analyses can be considered truly replicable. The extent to which this 
criterion is met within published analyses is currently unknown and is the subject of an ongoing research 
study [8]. This paper provides an overview of the different levels of, and motivations for, replicating 
health economic models, and discusses the advantages, disadvantages and caveats associated with this 
type of modelling activity. In addition, the feasibility of comprehensive model replication is explored 
empirically across a small number of recent case studies. Recommendations are put forward for 
improving reporting standards to enhance health economic model replicability.  
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MOTIVATIONS, ADVANTAGES AND DISADVANTAGES OF MODEL REPLICATION 
Purposes of model replication 
There are several motivations for replicating published models and their associated analyses. For 
example, a model author may wish to evaluate a new intervention or assess an existing intervention 
against different comparators using a model structure which has been previously defined and agreed as 
being appropriate as part of an earlier decision-making process. Alternatively, a model author adopting 
one particular modelling methodology may wish to reproduce a published model using an alternative 
approach in order to compare and contrast the results. In other instances, model authors may seek to 
replicate an existing model structure and accompanying parameter inputs in order to revise certain 
structural assumptions that are deemed inappropriate for the current decision problem, to incorporate 
alternative and/or newer evidence, and/or to adapt the model parameters to reflect the same decision 
problem within a different geographical health care jurisdiction. Model replication may also be 
undertaken retrospectively for the purposes of cross-validation: for example, the structure and/or 
parameters of a new model may be manipulated to determine whether it can produce similar results to 
previously published analyses. Across all of these situations, there is a necessary underlying assumption 
that the conceptual basis of the published model structure is adequate to address the current decision 
problem, or at least that it does not prohibit any necessary adaptation required to fully address the 
current decision problem. 
 
Levels of model replication 
Broadly speaking, model replication can be thought of in terms of a spectrum of activity which is 
dependent both on the purpose of the replication exercise and the extent to which that replication is 
implemented. At one end of the spectrum, the model author may attempt to comprehensively replicate 
a published model in its entirety, with the intention of reproducing the exact results presented in a study 
publication or report (e.g. an incremental cost-effectiveness ratio [ICER] for a given economic 
comparison or set of comparisons). There are several examples of comprehensive model replication in 
the literature. For example, Woods and Rizzo replicated a previous model of antidepressant therapies 
in order to revise the key assumptions around success rates and treatment duration which influenced the 
ICER [9]. In another example, Smolen et al. replicated a published model of onabotulinumtoxinA for 
the treatment of chronic migraine, originally developed by Batty et al. [10], for the purposes of future 
adaptation and expansion [11]. 
 
At the other end of the spectrum, the model author may attempt to replicate only the published model 
structure, without fully mimicking the decision problem in which that structure was originally applied. 
In such instances, the goal is not to reproduce the published ICER, and the replicator cannot fully ensure 
that the original model has been accurately replicated without doing so. Rather, the intention is to 
³ERUURZ´WKHpublished model structure to address a different decision problem to that for which it was 
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initially developed. 7KHUHDUHQXPHURXVH[DPSOHVRI³ERUURZLQJ´existing model structures within the 
published literature as well as within independent health technology assessment reports and 
pharmaceutical company submissions to health care reimbursement agencies. For example, the general 
hybrid decision tree/Markov structure developed for the assessment of glycoprotein IIb/IIIA antagonists 
for the treatment of non-ST elevation acute coronary syndromes (ACS) developed by Palmer et al. [12] 
(later cited in Briggs et al. [1]) was subsequently used to inform appraisals of other products within the 
National Institute for Health and Care Excellence (NICE) Technology Appraisal Programme, including 
ticagrelor for the treatment of ACS [13] and bivalirudin for the treatment of ST-segment-elevation 
myocardial infarction [14]. Similarly, the School of Health and Related Research (ScHARR) Multiple 
Sclerosis (MS) Model [15], which was oriJLQDOO\ GHYHORSHG WR LQIRUP 1,&(¶V DSSUDLVDO RI EHWD
interferon and glatiramer acetate, despite various modifications and adaptations [16], is cited as the 
source of the general model structure used by the manufacturers of products in all subsequently 
completed NICE appraisals of disease-modifying therapies for MS [17-21]. A further example is the 
York Psoriasis Model: this model was initially developed within NICE Technology Appraisal 103 [22] 
and was explicitly adopted by the manufacturers in subsequent appraisals of infliximab [23], 
adalimumab [24], and ustekinemab [25].  
 
Alternatively, the model author may attempt to replicate a published model for use in part of their de 
novo model structure. This involves replicating the published model structure and inputs for use as a 
³VXE-PRGHO´ within the broader structure of the new model (although in some instances it may be 
possible to simply use the original model outputs as input parameters to the new model without fully 
replicating its structure). For example, within their economic analysis of oxaliplatin and capecitabine 
for the adjuvant treatment of colon cancer, Eggington et al. [26] replicated a model of treatments for 
metastatic colorectal cancer [27] to inform downstream costs and health outcomes for relapsed patients 
(in this case, the original model was available hence it was unnecessary to fully rely on the reporting of 
the study publication). In another example, Kearns et al. [28] produced a model simulating joint costs 
and outcomes of service reconfiguration options for type 2 diabetes and depression which involved 
replicating the underlying structure and inputs of a published depression model [29] and the United 
Kingdom Prospective Diabetes Study (UKPDS) outcomes model (version 2) [30-32] based on the study 
publications. 
 
The advantages and disadvantages of model replication  
Irrespective of the extent to which it is applied, model replication may be associated with two clear 
advantages. Firstly, replicating an existing model may require considerably less effort, time and expense 
than developing a de novo model as a consequence of bypassing, or undertaking in only a perfunctory 
manner, certain stages of model development such as conceptual modelling and/or extensive literature 
searching for parameters. Secondly, the use of a previously accepted model structure and previously 
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identified evidence sources may increase a decision-maNHU¶V FRQILGHQFH LQ WKH DQDO\VLV RI WKH QHZ
technology. IQWKLVVHQVHLWLVQRWRQO\WKHPRGHOVWUXFWXUHDQGLQSXWVZKLFKDUHEHLQJ³ERUURZHG´EXW
also the credibility or perceived prestige of the original model arising from its publication in a peer 
reviewed journal or from its acceptance and use by decision-makers. Model replication may however 
also be associated with some important disadvantages. In particular, two key underlying assumptions 
associated with the use of replicated models should be noted: (i) the existing model structure is suitable 
to address the new decision problem, and; (ii) the existing model was suitable to address the decision 
problem for which it was originally intended. Importantly, neither of these assumptions necessarily hold 
true.  
The first assumption may be unsound for older publications of models which fare poorly when judged 
against currently accepted views of best practice, for models which do not adhere to current economic 
reference cases, and for those which reflect outdated theories of disease natural history or outdated 
treatment pathways and/or evidence. For example, in the NICE technology appraisal of bosutinib for 
previously treated chronic myeloid leukaemia (CML) [33], the company used an approach to 
extrapolate overall survival from a surrogate relationship between major cytogenetic response and 
overall survival that was based on an analysis undertaken within a previous appraisal for another 
treatment for CML [34]. The Appraisal Committee concluded that there was considerable uncertainty 
whether a study that had assessed imatinib escalation for CML could plausibly apply to bosutinib in the 
third-line setting. A further example of questionable model replication can also be found in the NICE 
technology appraisal of multiple biologic treatments for rheumatoid arthritis (RA). In this appraisal 
[35], all six companies submitted models which, based on previous appraisals [36, 37], made the 
structural assumption that Health Assessment Questionnaire Disease Index (HAQ DI) increased linearly 
while on conventional treatments. Conversely, the Assessment Group modelled non-linear HAQ DI 
trajectories using a latent class approach based on a recent relevant study by Norton et al. [38]. Finally, 
in the NICE appraisal of olaparib for relapsed ovarian cancer, the company justified their semi-
Markovian model structure through reference to the previous appraisal of bevacizumab for the first-line 
treatment of ovarian cancer, although the exact definitions of health states differed between the models. 
7KH(5*KDGVHULRXVFRQFHUQVUHJDUGLQJWKHUHVWULFWLYHDVVXPSWLRQVDGRSWHGZLWKLQWKH³ERUURZHG´
structure and its inability to generate plausible overall survival predictions which reflected the empirical 
results of the trial used to inform WKHPRGHO¶VSDUDPHWHUV (an issue which was most likely caused by the 
adopted structure). The Appraisal Committee noted that WKHFRPSDQ\¶VVWUXFWXUHZDV³XQFRQYHQWLRQDO´
and expressed concerns regarding the plausibility of the extrapolation of overall survival data generated 
using WKHFRPSDQ\¶VDGRSWHGVWUXFWXUH.  
The assumption that the replicated model was suitable to address the decision problem for which it was 
originally intended may also be invalid as neither the prior acceptance and use of a model by a decision-
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maker nor the journal peer review process are perfect signals of model quality. Consequently, there is 
a risk that what is perceived to have been suitable before is not suitable now, and may never have been 
suitable in the first place. It should further be recognised that when adopting an existing structure it 
would be unwise to entirely bypass the development of a de novo conceptual model. On the contrary, 
the new conceptual model should be compared with models identified through literature searches and 
should be discussed with clinical and economic experts to ensure its appropriateness. Failure to do so 
may lead to the loss of an important point of model validation [39] and can impose restrictions on the 
available choices about how evidence can best be used to inform the current decision problem. Thus, 
whilst the intention of model replication may be to borrow credibility from an existing structure, its 
unthinking use may produce the converse result.  
 
FEASIBILITY OF COMPREHENSIVE MODEL REPLICATION ± A PILOT STUDY 
If a model developer intends to replicate a model and its results, the advantages of such activity can 
only be realised if the published model is actually fully replicable. In order to assess the feasibility of 
comprehensive model replication, we undertook a small pilot study in which we attempted to fully 
reproduce five recent economic analyses published in Pharmacoeconomics between August and 
November 2016 [40-44]. For each study, the feasibility of replicating the analyses was explored through 
consideration of published information relating to model structure, assumptions and model parameter 
values (see Table 1) within the full study publication and any supplementary material available online, 
but excluding information reported in other papers or reports. As one of the included models was 
developed by one of the authors of this paper (PT), the replication of this model was undertaken 
independently by a different author (IB).  
 
Across the five case studies, our model replication efforts were met with limited success: two models 
were fully replicated (Versteegh  [44] and Tappenden et al. [41]), two models were unequivocally not 
replicable (Oddershede et al. [43] and Davies et al. [42]),  and one model was potentially replicable 
although the replication process failed in this instance (Elvidge et al. [40]). In the two instances whereby 
the models were reproduced, there were discrepancies between the replicated model results and those 
reported within the study publications.  
 
The model reported by Davies et al. was based on analyses of the published CORE diabetes model 
(McEwan et al. [45]) which has been previously used to inform a number of reimbursement decisions. 
This paper included a model structure diagram but only parameter values relating to the baseline 
characteristics of the model population and treatment effect parameters. Resource use and cost 
parameters were reported as supplementary material, however, the event probabilities and risk equations 
were not. Consequently, full model replication failed. The paper by Oddershede et al. [43] was 
principally an economic evaluation alongside a clinical trial (EEACT), but included long-term 
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modelling beyond the observed study period using generalised linear models (GLMs) [46]. These 
GLMs were calculated from individual patient data and no details were provided on their covariates or 
coefficients; as such, it was not possible to replicate the published results. Within the paper reported by 
Elvidge et al. [40]), the reporting of the model structure and parameter inputs was generally clear, 
however the model structure diagram did not exactly match the implemented model, a finding which 
was determined through subsequent personal communication with the authors. As a consequence of this 
ambiguity, the replication of the Elvidge et al model was abandoned. With respect to the model by 
Tappenden et al. [41], replication was possible, as the description of the model structure was clear and 
the list of parameters used in the model was fully reported. However, some reported event probabilities 
were subject to rounding errors which led to differences between the published results and those 
generated using the replicated model. Based on the information provided in the paper and the 
supplementary material, the analyses reported by Versteegh [44] were simple to reproduce, although 
minor additional assumptions around other-cause mortality and half-cycle correction were required. 
However, whilst the modelled incremental health gains were broadly similar between the replicated 
model and the original publication, the incremental costs remained consistently lower in the replicated 
model, thereby also affecting the accuracy of the ICERs. A second author (JY) independently attempted 
to replicate the Versteegh model; however, this further analysis produced similar discrepancies to the 
first replicated model. 
 
Table 1: Feasibility of comprehensive model replication across five published case study models 
[INSERT TABLE 1 HERE] 
 
BARRIERS AND FACILITATORS  
Barriers to comprehensive model replication 
Several barriers may hinder or preclude comprehensive model replication. In particular, these include:  
x Inadequate and/or insufficient reporting of the model and/or its inputs: This may relate to the 
exclusion of certain model parameters or a lack of correspondence between the implemented 
model and the reported model. Insufficient reporting of the model may lead to a situation 
whereby analysts must make assumptions about the model structure and/or its parameters; this 
can lead to discrepancies in the replicated model results.  
x The use of ambiguous language: The description of the implemented model may be ambiguous 
and open to multiple interpretations; this may affect all forms of model replication and may 
lead to discrepancies in replicated model results.  
x Confidentiality of model inputs: Confidentiality of input parameters represents a particular 
problem in some UK-analyses undertaken to inform the NICE Technology Appraisal 
Programme as manufacturers of a product may offer a confidential price discount as part of a 
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Patient Access Scheme (PAS). Unless the ICERs generated using the list prices of the products 
are available, it is unlikely that full model replication will be possible. In addition, the published 
model may have been parameterised using datasets that are not publicly available. 
Comprehensive replicability of the health economic model may also require full disclosure of 
all statistical models used to derive the health economic model parameters.  
x Reporting limits: Journal publication limits may restrict full reporting of models. This is likely 
to be an issue for highly complex models and/or those which feature a large number of 
parameters. In addition, the implementation of complex model assumptions and algorithms, for 
example, patient-level simulations involving multiple competing events and updating of events, 
may be technically challenging to reproduce and may require additional assumptions which 
deviate from those applied in the original model. 
x Errors in original publications: Unidentified programming errors in the original model may 
lead to difficulties in replicating published model results. 
 
Alongside the barriers described above, other practical difficulties may also arise. For example, if a 
different modelling methodology is adopted for comparison purposes, e.g. converting a published 
Markov model to a discrete event simulation, parameter inputs may need to be re-estimated to reflect 
the data structures of the new methodology. This may require additional assumptions as well as new 
statistical analyses. In instances whereby the original structure is used but the data inputs are updated, 
some aspects of the structural arrangement and model assumptions may be revised to reflect the 
structure of the new data and the characteristics of the target population. In certain instances, the original 
structure of the published model may have been heavily influenced by the nature of the event risk data; 
if the model structure is to be replicated and subsequently adapted to reflect costs and outcomes for a 
different population, the existing structure may no longer be able to accommodate the new data. Finally, 
the complexity of some models might render their full replication based solely on a published paper 
unrealistic. Modellers interested in replicating such models would be best advised to approach the 
authors of the replicated model. 
 
Suggestions for improving model replicability 
A recent survey of health economic stakeholders suggested that across all stakeholders and countries, 
making health economic models available in an open format was considered to be beneficial [47]. The 
provision of open source models would circumvent problems around model replicability. This is 
however not universal practice; in the absence of such a policy, the following suggestions may serve to 
improve the replicability of published models. 
x The stronger enforcement of transparent reporting standards such as the CHEERS checklist [4]) 
may increase the number of models which are fully replicable. Most importantly, publications 
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describing models should include a comprehensive description of the model structure and a full 
list of model assumptions and input parameters. The use of supplementary appendices may be 
helpful in this regard. Wherever possible, model authors should seek to lift confidentiality of 
all input parameters prior to publication. Ensuring model replicability is principally the concern 
of the model author, the main incentive for which is the increased credibility of the model 
through its transparent reporting. 
x Model authors should ensure that the description of the model structure, assumptions and 
parameter sources presented in written documentation reflects the implemented model. 
Specifically, authors should ensure that diagrams and text are not ambiguous or open to 
multiple interpretations. For highly complex models, the use of separate diagrams for parts of 
the model may be helpful.  
x Publishers could require submitting authors to include a statement in any written documentation 
confirming that the model and its results could, in principle, be reproduced by a competent 
analyst. 
x Improving reporting of exact data sources and relevant analytic methods used to analyse those 
data may increase the transparency of parameter estimation. This includes not only citing 
studies which report the general specifications of the dataset, but also providing information 
about how the data have been used within the model.   
 
CONCLUSIONS 
Model replication can take several forms, ranging from comprehensive reproduction of the model 
structure and its results to the borrowing of a previously accepted model structure. Comprehensive 
replicability is generally perceived to be a desirable property of health economic models, however, the 
acceptability and appropriateness of using previously published models depends on the decision-
making context; when this type of modelling activity is pursued, model authors should be mindful of 
any important aspects of the model development process which have been omitted, the relevance of the 
replicated model to the current decision problem, as well as any criticisms levied against the original 
model. Our pilot study indicates that from only a very small sample of economic modelling studies, 
comprehensive model replication is not always possible; further analyses are required to clarify the 
extent of this problem.   
 
Data Availability Statement 
The replicated models generated during the current study are available from the corresponding author 
on reasonable request. 
 
Compliance with Ethical Standards  
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IB, PT and JY did not receive any funding to support the drafting of this manuscript and have no 
conflicts of interest to declare. PT attempted to replicate four of the five models included in the pilot 
study. IB replicated the remaining model. JY replicated one of the models. IB, PT and JY were involved 
in writing the manuscript.  
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Table 1: Feasibility of comprehensive model replication across five published case study models 
Authors Title Disease 
area  
Model 
type 
Model 
structure 
diagram 
reported 
List of 
assumptions 
reported 
Full parameter list 
reported 
Was full replication 
successful? 
Elvidge et 
al [40] 
Cost effectiveness of characterised 
chondrocyte implantation for 
treatment of cartilage defects of 
the knee in the UK 
Knee 
defects 
Markov Yes  Yes. Provided 
in text 
Yes. Supplementary 
appendix provides 
survival model 
parameters and 
distributions. 
No. The model structure 
diagram does not exactly 
match states in implemented 
model. This led to some 
difficulty in fully mapping 
the transition probability 
inputs to the state transition 
matrix. 
Versteegh 
[44] 
Impact on the incremental cost-
effectiveness ratio of using 
alternatives to EQ-5D in a Markov 
model for multiple sclerosis  
Multiple 
sclerosis 
Markov Yes Yes. Provided 
in text and 
supplementary 
material 
Yes, excluding life 
tables. 
Yes, but with discrepant 
results.  
 
Tappenden 
et al [41] 
A model-based economic 
evaluation of biologic and non-
biologic options for the treatment 
of adults with moderately-to-
severely active ulcerative colitis 
after the failure of conventional 
therapy  
Ulcerative 
colitis 
Markov Yes Yes Yes, excluding life 
tables. 
Yes. Minor differences 
between published and 
replicated results, likely due 
to rounding errors. 
Oddershede 
et al [43] 
Cost effectiveness of protease 
inhibitor monotherapy versus 
standard triple therapy in the long-
term management of HIV patients: 
Analysis using evidence from the 
PIVOT trial  
HIV 
treatment 
EEACT 
with long-
term 
modelling 
No No No. Restricted to 
resource use parameters. 
No. GLM equations were 
not reported, hence survival 
and QALY estimates could 
not be replicated for either 
treatment group 
Davies et al 
[42] 
Cost effectiveness of IDegLira vs. 
alternative basal insulin 
intensification therapies in patients 
with type 2 diabetes mellitus 
Type 2 
diabetes 
mellitus 
Patient-
level 
simulation 
Yes No No. Event probabilities 
not reported. 
No. 
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uncontrolled on basal insulin in a 
UK setting  
Abbreviations: EEACT, economic evaluation alongside a clinical trial; EQ-5D, EuroQol 5 dimensions questionnaire; HIV, human immunodeficiency virus; 
GLM: generalised linear model; QALY: quality-adjusted life year 
